ANTABIO has developed a rich portfolio of first-in-class programs targeting high unmet needs in the antibacterial space. In 2013 ANTABIO received a €4.7 Million Wellcome Trust Seeding Drug Discovery Award to fund the development of a novel, safe and efficacious inhibitor of bacterial metallo ß-lactamases up to preclinical candidate nomination. In 2015, ANTABIO received a second Wellcome Trust Seeding Drug Discovery Award (€4.0 Million) to support the development of novel small molecule drugs for the treatment of chronic Pseudomonas infections in Cystic Fibrosis (CF) patients. In addition, ANTABIO has established an industrial discovery engine supported by Bpifrance (the French public investment bank) which is dedicated to the discovery, evaluation and development of new combination and/or adjunctive antibiotic therapies.
MBLi: Metallo Beta-Lactamases inhibitors
Antibiotic resistance is a growing global health problem recognized as n°1 priority by the WHO. 5-10% of hospital patients in US and Europe develop a hospital-acquired (nosocomial) infection with annual > €30 billion additional costs to public health and > 100,000 deaths due to drug-resistant bacterial infections.
Current antibacterial chemotherapy is becoming increasingly inadequate due to the rise of clinical resistance, mainly related to the spread of genes encoding various carbapenemases, including the metallo ß-lactamase (MBL) enzymes of the NDM and VIM types, for which no inhibitors are currently available or under clinical development.
ANTABIO is developing a novel, safe and efficacious inhibitor of bacterial MBLs. It will be co-administered with a carbapenem to treat hospitalized patients suffering from complicated Gram-negative infections.
ANTABIO’s lead compounds potentiate the efficacy of the carbapenem antibiotic meropenem against E. coli NDM-1 strains in animal infection models, and are active against a broad range of MBL-containing clinical isolates in laboratory susceptibility studies. Further optimization towards preclinical candidate selection is in progress.
PBi : Pseudomonas Biofilms inhibitors
Cystic fibrosis (CF) is a life-threatening disease, caused by mutation in the CFTR chloride channel, affecting ~70,000 sufferers worldwide. The majority (69-80%) of adult CF patients have chronic Pseudomonas aeruginosa lung infections, due to impaired ciliary clearance, causing progressive lung damage and early death.
Despite intensive antibiotic treatment, adaptive mechanisms such as biofilm formation allow Pseudomonas to resist both immune and antibiotic pressures, leading to recurrent exacerbations and respiratory failure.
ANTABIO is developing an inhaled drug which can be used as an adjunct to existing antibiotic therapy and which will reduce the frequency and severity of Pseudomonas exacerbations by targeting both the virulence and persistence of biofilm-adapted infections.
ANTABIO has developed a tractable lead series with potent whole cell activity against clinical Pseudomonas isolates and excellent potential for inhaled administration. Further optimization towards development of in vivo leads is in progress.